JP2008504022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504022A5 JP2008504022A5 JP2007517457A JP2007517457A JP2008504022A5 JP 2008504022 A5 JP2008504022 A5 JP 2008504022A5 JP 2007517457 A JP2007517457 A JP 2007517457A JP 2007517457 A JP2007517457 A JP 2007517457A JP 2008504022 A5 JP2008504022 A5 JP 2008504022A5
- Authority
- JP
- Japan
- Prior art keywords
- tau protein
- tyrosine kinase
- inhibitor
- substance
- phosphorylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 30
- 102000013498 tau Proteins Human genes 0.000 claims 29
- 108010026424 tau Proteins Proteins 0.000 claims 29
- 239000000126 substance Substances 0.000 claims 16
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 15
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 15
- 230000026731 phosphorylation Effects 0.000 claims 8
- 238000006366 phosphorylation reaction Methods 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000000758 substrate Substances 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- JWQOJVOKBAAAAR-UHFFFAOYSA-N 2-[[7-(3,4-dimethoxyphenyl)-5-imidazo[1,2-c]pyrimidinyl]amino]-3-pyridinecarboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=NC=CN2C(NC=2C(=CC=CN=2)C(N)=O)=N1 JWQOJVOKBAAAAR-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010056677 Nerve degeneration Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000007837 multiplex assay Methods 0.000 claims 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000009822 protein phosphorylation Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58090104P | 2004-06-21 | 2004-06-21 | |
| US60/580,901 | 2004-06-21 | ||
| PCT/GB2005/002475 WO2005123048A2 (en) | 2004-06-21 | 2005-06-21 | Screening methods using c-abl, fyn and syk in combination with tau protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011195901A Division JP5668201B2 (ja) | 2004-06-21 | 2011-09-08 | スクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008504022A JP2008504022A (ja) | 2008-02-14 |
| JP2008504022A5 true JP2008504022A5 (enExample) | 2008-07-24 |
| JP5058792B2 JP5058792B2 (ja) | 2012-10-24 |
Family
ID=35064772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007517457A Expired - Fee Related JP5058792B2 (ja) | 2004-06-21 | 2005-06-21 | スクリーニング方法 |
| JP2011195901A Expired - Fee Related JP5668201B2 (ja) | 2004-06-21 | 2011-09-08 | スクリーニング方法 |
| JP2014150904A Pending JP2014198054A (ja) | 2004-06-21 | 2014-07-24 | スクリーニング方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011195901A Expired - Fee Related JP5668201B2 (ja) | 2004-06-21 | 2011-09-08 | スクリーニング方法 |
| JP2014150904A Pending JP2014198054A (ja) | 2004-06-21 | 2014-07-24 | スクリーニング方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8367360B2 (enExample) |
| EP (2) | EP1794313B1 (enExample) |
| JP (3) | JP5058792B2 (enExample) |
| AU (1) | AU2005253776B8 (enExample) |
| CA (1) | CA2571614C (enExample) |
| DK (1) | DK1794313T3 (enExample) |
| ES (1) | ES2415665T3 (enExample) |
| WO (1) | WO2005123048A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009506302A (ja) * | 2005-08-04 | 2009-02-12 | イェシバ・ユニバーシティ | Ａｂｌによるタウのリン酸化 |
| ES2318616T3 (es) * | 2006-06-01 | 2009-05-01 | Cellzome Ag | Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70. |
| WO2008009000A2 (en) * | 2006-07-13 | 2008-01-17 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in signaling pathways |
| WO2008057599A2 (en) * | 2006-11-10 | 2008-05-15 | Intra-Cellular Therapies, Inc. | Methods for the treatment of abeta related disorders and compositions therefor |
| WO2008145789A1 (es) * | 2007-05-28 | 2008-12-04 | Pontificia Universidad Catolica De Chile | Uso de compuestos derivados de benzamidina metanosulfonato o su sal farmacéuticamente aceptable, por ejemplo mesilato de imatinib, para preparar un medicamento para el tratamiento de la enfermedad neurodegenerativa de niemann pick de tipo c ( npc). |
| WO2009143556A1 (en) * | 2008-05-30 | 2009-12-03 | The University Of Sydney | TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION |
| RU2595720C2 (ru) | 2009-04-09 | 2016-08-27 | Когнишн Терапьютикс, Инк. | Ингибиторы снижения когнитивных способностей |
| US9192585B2 (en) | 2009-07-31 | 2015-11-24 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| WO2011044537A2 (en) * | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | Methods for treating alzheimer's disease |
| WO2011106785A2 (en) * | 2010-02-26 | 2011-09-01 | Cognition Therapeutics, Inc. | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| RU2013140467A (ru) | 2011-02-02 | 2015-03-10 | Когнишн Терапьютикс, Инк. | Выделенные соединения из масла куркумы и способы применения |
| WO2013148283A1 (en) | 2012-03-30 | 2013-10-03 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| WO2013166295A1 (en) | 2012-05-02 | 2013-11-07 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| EP2852388A4 (en) * | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| KR101582852B1 (ko) * | 2012-05-24 | 2016-01-07 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
| JP2014147365A (ja) * | 2013-02-04 | 2014-08-21 | Osaka City Univ | オリゴヌクレオチド構造体および遺伝子発現抑制方法 |
| CN111254145A (zh) | 2013-03-14 | 2020-06-09 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
| CN104230770B (zh) * | 2013-06-17 | 2017-11-21 | 华夏生生药业(北京)有限公司 | 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用 |
| TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| JP6342627B2 (ja) * | 2013-08-02 | 2018-06-13 | 国立大学法人 東京大学 | 筋萎縮性側索硬化症の新規病因遺伝子 |
| AU2015210852B2 (en) | 2014-01-31 | 2019-01-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| KR20160127825A (ko) * | 2014-03-12 | 2016-11-04 | 프로테나 바이오사이언시즈 리미티드 | 항-mcam 항체 및 관련된 사용 방법 |
| US20180311236A1 (en) * | 2015-10-28 | 2018-11-01 | Ab Science | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease |
| JP2017131191A (ja) * | 2016-01-29 | 2017-08-03 | 国立大学法人京都大学 | 疾患の予防及び／又は治療剤のスクリーニング方法 |
| ES2963428T3 (es) | 2016-09-29 | 2024-03-27 | Biogen Ma Inc | Compuestos y métodos para reducir la expresión de Tau |
| DK3634394T3 (da) | 2017-05-15 | 2026-03-02 | Cognition Therapeutics Inc | Sammensætninger til behandling af neurogenerative sygdomme |
| WO2018216705A1 (ja) * | 2017-05-23 | 2018-11-29 | 国立大学法人京都大学 | 神経変性疾患の予防及び／又は治療剤 |
| JP7197864B2 (ja) * | 2017-05-31 | 2022-12-28 | 公立大学法人名古屋市立大学 | アルツハイマー病バイオマーカー |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| BR112020018365A2 (pt) * | 2018-03-13 | 2020-12-29 | Janssen Pharmaceutica Nv | Oligonucleotídeos modificados e métodos para uso em tauopatias |
| CN113272308B (zh) | 2018-11-20 | 2025-03-18 | 乔治敦大学 | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN110702665B (zh) * | 2019-11-14 | 2022-03-22 | 济南大学 | 一种纸基耦合增强拉曼传感器制备及其在大田软海绵酸检测中的应用 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2024064729A1 (en) * | 2022-09-20 | 2024-03-28 | University Of Virginia Patent Foundation | Syk activators and inhibitors in neurodegenerative diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5514778A (en) * | 1993-07-01 | 1996-05-07 | Eli Lilly And Company | Anti-picornaviral agents |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| AU2003234567A1 (en) * | 2002-05-15 | 2003-12-02 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| GB0314943D0 (en) * | 2003-06-25 | 2003-07-30 | Proteome Sciences Plc | Screening methods |
-
2005
- 2005-06-21 EP EP05755789.4A patent/EP1794313B1/en not_active Expired - Lifetime
- 2005-06-21 ES ES05755789T patent/ES2415665T3/es not_active Expired - Lifetime
- 2005-06-21 EP EP10010717.6A patent/EP2441847B1/en not_active Expired - Lifetime
- 2005-06-21 WO PCT/GB2005/002475 patent/WO2005123048A2/en not_active Ceased
- 2005-06-21 AU AU2005253776A patent/AU2005253776B8/en not_active Ceased
- 2005-06-21 CA CA2571614A patent/CA2571614C/en not_active Expired - Fee Related
- 2005-06-21 DK DK05755789.4T patent/DK1794313T3/da active
- 2005-06-21 JP JP2007517457A patent/JP5058792B2/ja not_active Expired - Fee Related
- 2005-06-21 US US11/630,720 patent/US8367360B2/en not_active Expired - Fee Related
-
2011
- 2011-09-08 JP JP2011195901A patent/JP5668201B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-21 US US13/683,375 patent/US20130123133A1/en not_active Abandoned
-
2014
- 2014-07-24 JP JP2014150904A patent/JP2014198054A/ja active Pending
-
2015
- 2015-08-17 US US14/827,364 patent/US20160186233A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012024094A5 (enExample) | ||
| Pagan et al. | Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease | |
| EP1891446B1 (en) | Process for the identification of novel enzyme interacting compounds | |
| Collins et al. | Phosphoproteomic analysis of the mouse brain cytosol reveals a predominance of protein phosphorylation in regions of intrinsic sequence disorder | |
| Nunes et al. | RhoA/Rho-kinase and vascular diseases: what is the link? | |
| Perez et al. | Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds | |
| Wen et al. | CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease | |
| JP5668201B2 (ja) | スクリーニング方法 | |
| JP7241104B2 (ja) | アルツハイマー病に関係する生体分子 | |
| Simard et al. | High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38α | |
| US20090253156A1 (en) | Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases | |
| EP1395261B1 (en) | Pyridylpyrimidine derivatives as effective compounds against prion diseases | |
| Cinelli et al. | Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition | |
| WO2001032156A3 (en) | Methods for treating fibroproliferative diseases | |
| Pensa et al. | Hydrophilic, potent, and selective 7-substituted 2-aminoquinolines as improved human neuronal nitric oxide synthase inhibitors | |
| Yao et al. | One-step SH2 superbinder-based approach for sensitive analysis of tyrosine phosphoproteome | |
| HK1255804A1 (zh) | 作为双重dyrk1/clk1抑制剂的新的咪唑并[4，5-b]吡啶衍生物 | |
| EP1527345A2 (en) | Method for isolating atp binding proteins by means of immobilized protein inhibitors | |
| AU2004252273B2 (en) | Screening methods | |
| Edbauer et al. | Identification and Characterization of Neuronal Mitogen-activated Protein Kinase Substrates Using a Specific Phosphomotif Antibody* S | |
| Qian et al. | Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases | |
| Rodrigues et al. | Discovery of potential neurodegenerative inhibitors in Alzheimer’s disease by casein kinase 1 structure-based virtual screening | |
| Hou et al. | NBS1 deficiency promotes genome instability by affecting DNA damage signaling pathway and impairing telomere integrity | |
| Weßbecher et al. | Phosphorylation meets DNA mismatch repair | |
| JP4932835B2 (ja) | 酵素と相互作用する新規化合物の同定法 |